New strategies in the treatment of refractory forms and relapses of follicular lymphoma: CAR T-cell therapy

Introduction. Follicular lymphoma (FL) is the most common indolent lymphoma. Despite the long overall survival, the tumor remains incurable in most patients. Currently, there is no specific algorithm for choosing therapy for ≥3 lines of patients with FL. CAR T-cell therapy (therapy with genetically modified T-lymphocytes carrying a chimeric antigen receptor — CAR) has proven effective in many tumors, including FL. Aim . to systematize data on the efficacy and safety of modern CAR T-cell therapy for follicular lymphoma. Main fi ndings. CAR T-cell therapy is an effective option both for patients with FL after multiple courses of therapy, and for refractory tumors. Ongoing advancements continue to refine this method, enhancing its safety and expanding the possibilities of use. CAR T-cell therapy is increasingly being integrated into anti-relapse regimens for FL.